$ADXS The Week Ahead in Biotech, Benzinga: ASCO 2020 Genitourinary Cancers Symposium Presentations Exelixis, Inc. (NASDAQ: EXEL): Phase 1b data for cabozantinib and Roche Holdings AG Basel ADR Common Stock's (OTC: RHHBY) Tecentriq in solid tumors (Thursday) Advaxis, Inc. (NASDAQ: ADXS): Phase 1/2 data for ADXS-PSA and Merck's Keytruda from the KEYNOTE-046 study in castrate-resistant prostate cancer (Thursday) TrovaGene Inc (NASDAQ: TROV): new Phase 2 data for onvansertib and zytiga in prostate cancer (Thursday) Corvus Pharmaceuticals Inc (NASDAQ: CRVS): updated Phase 1b/2 data for CPI-444 in solid tumors
  • 6
  • 2